Share ownership Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-12 EDT			5-day change	1st Jan Change
30.90 ^USD	-0.58%		-10.12%	+6.77%

09-04	Transcript : Supernus Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 04:30 PM
08-19	Sector Update: Health Care Stocks Edge Higher Premarket Monday	MT

Share class: Supernus Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	55,105,387	52,334,037 ( 94.97 %)	0	94.97 %

Major shareholders: Supernus Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 17.72 %	9,767,027	17.72 %	343 M $
Vanguard Fiduciary Trust Co. 11.14 %	6,137,541	11.14 %	216 M $
Armistice Capital LLC 9.567 %	5,272,000	9.567 %	185 M $
DFA Australia Ltd. 5.034 %	2,773,982	5.034 %	98 M $
Macquarie Investment Management Business Trust 4.863 %	2,679,796	4.863 %	94 M $
State Street Corp. 3.927 %	2,163,841	3.927 %	76 M $
Jack Khattar 3.536 %	1,948,622	3.536 %	69 M $
Polar Capital Holdings Plc 3.521 %	1,940,510	3.521 %	68 M $
Stephens Investment Management Group LLC 3.445 %	1,898,499	3.445 %	67 M $
BNY Mellon Investment Adviser, Inc. 3.119 %	1,718,702	3.119 %	60 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	92.65%
Other	7.58%
Individuals	4.26%
State Street Corp.	3.93%
Polar Capital Holdings Plc	3.52%
SEI Investments Co.	0.61%
Schweizerische Nationalbank	0.20%
Corebridge Financial, Inc.	0.05%
Manulife Financial Corp.	0.05%
Governments	0.03%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	90.58%
United Kingdom	7.09%
Australia	5.06%
Individuals	4.26%
Switzerland	1.62%
Ireland	1.30%
Canada	0.77%
Belgium	0.69%
Norway	0.46%
Germany	0.30%
France	0.29%
Luxembourg	0.26%
Finland	0.05%
Denmark	0.04%
Sweden	0.03%
Cayman Islands	0.03%
Netherlands	0.02%
New Zealand	0.01%
China	0.01%
Spain	0.01%

Based on 1000 largest holdings

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Employees

652

Sector

Pharmaceuticals

Calendar

2024-11-04 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company